Complement Factor P (Properdin) Drug Discovery Landscape & Assay Solutions
- By admin
- 17 Aug 2026
- Comments
Market Intelligence for Alternative Complement Pathway Inhibitors in PNH, aHUS, and Immuno-Oncology.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CFP (Complement Factor P / Properdin) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CFP ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View CFP Products |
| Gene Delivery | CFP Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and secreted protein expression. | View CFP Products |
| Benchmark Ab | Anti-CFP (Sequence of Benchmark Inhibitor) Recombinant positive control for assay development. | View CFP Products |
| Validator | CFP siRNA Set For knockdown verification and specificity controls. | View CFP Products |
| Related Target (C3) | Complement C3 Core component of the C3bBb convertase stabilized by CFP. Essential for convertase formation assays. | View C3 Products |
| Related Target (C5) | Complement C5 Downstream complement effector target for synergistic inhibition. | View C5 Products |
| Related Target (Factor B) | Complement Factor B Alternative pathway C3 convertase component, partner in the C3bBb complex. | View Factor B Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, Sequence Verified |
| Native conformation for convertase binding | HEK293 Expressed (Native Glycosylation), strictly verified by mass spec |
| Pathway Selectivity (Alternative vs. Classical/Lectin) | High-purity CFP for specific alternative pathway assays; C3b deposition control proteins |
| Functional Validation (C3 Convertase Regulation) | Unmodified CFP wild-type and mutant variants (TSR domains) for mechanistic studies |
| Lack of Controls | Clinical Benchmark Antibodies included for assay calibration |
| False Positives | Validated siRNA included for specificity checks |
Live CFP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CFP (Properdin) therapeutics is intensifying, with major players shifting focus from systemic broad complement inhibition to targeted alternative pathway (AP) regulation. As the only known positive regulator of the AP, CFP represents a unique node to halt AP-driven diseases (such as PNH, aHUS, and geographic atrophy) while leaving the classical and lectin pathways intact for microbial defense. Unlike C5 inhibitors that act downstream, CFP-targeted agents promise broader immunomodulatory control with preserved classical pathway function. The next wave of R&D is targeting subcutaneous delivery and bispecific constructs that tether complement regulators directly to specific tissue surfaces. Emerging indications in oncology (where complement activation drives immune evasion) are also gaining attention.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Novartis, Omeros | PNH, aHUS, C3G | Affinity Kinetics (Need high-purity CFP Protein) |
| Bispecific / Fusion | Apellis, Alexion | Geographic Atrophy, Renal Diseases | Complex Stabilization Assay (Need Native Glycosylation) |
| siRNA / RNAi | Alnylam, Arrowhead | Systemic Complement Disorders | Knockdown Validation (Need Sequence Verified siRNA) |
Key Molecular Features
Complement Factor P (CFP) contains three thrombospondin type-1 (TSP type-1) domains (UniProt P27918), which mediate interaction with C3b and Factor B in the alternative complement pathway. Clinically relevant mutations include: a somatic mutation in a breast cancer sample (VAR_035813); a type II PFD mutation that inhibits secretion and oligomerization (VAR_083038); and a common polymorphism in dbSNP:rs8177068 (VAR_020395). These variants impact properdin function and should be considered in drug development strategies.